Key Highlights

  • Revenue was USD 25.60 million against a USD 21.54 million estimate, with EPS of USD -0.32 against USD -0.26.
  • Pharma testing Revenue was USD 17.1 million, and clinical diagnostic revenue was USD 4.4 million against USD 0.4 million.
  • Net loss was USD 33.8 million against USD 21.7 million, with Research and Development expense of USD 16.1 million.
  • Cash and short-term investments were USD 190.6 million, and stockholders vote on the Tempus Merger on November 30, 2026.

Personalis, Inc. (NASDAQ:PSNL) reported third quarter revenue of USD 25.6 million against USD 14.5 million a year earlier, a change the company stated as 77%. The net loss was USD 33.8 million, or USD 0.32 per share, against USD 21.7 million, or USD 0.24. The company also has a pending merger with Tempus, and its stockholders are scheduled to vote on November 30, 2026.

Results and Revenue Drivers

Pharma testing services revenue was USD 17.1 million against USD 13.1 million, which the company tied to more clinical trial samples processed for Merck. Merck accounted for 22% of revenue. Population sequencing revenue under the VA Million Veteran Program was USD 4.1 million against USD 0.2 million, reflecting a planned increase in samples processed. Clinical diagnostic revenue was USD 4.4 million, which management linked to higher NeXT Dx test Volume and NeXT Personal Dx reimbursements following Medicare coverage decisions for breast cancer, lung cancer, immunotherapy monitoring and neoadjuvant therapy monitoring. Enterprise sales were USD 8,000 against USD 650,000 after the Natera relationship ended.

Cost of revenue was USD 19.0 million against USD 12.6 million, which the company attributed mainly to clinical diagnostic test costs where reimbursement was lower than testing cost as it sold tests ahead of Medicare reimbursement. Selling, general and administrative expense was USD 26.0 million against USD 13.0 million, and loss from operations was USD 35.5 million against USD 23.3 million.

Clinical Evidence and Product Updates

During the quarter the company launched the NeXT Personal Real-Time Variant Tracker, a supplemental result in its molecular residual disease report that identifies resistance and therapeutically targetable variants over time. It also reported pre-interim results from its prospective triple negative breast cancer study, with a 96% ctDNA detection rate at baseline and an 82% ctDNA clearance rate after two cycles of neoadjuvant therapy.

In August 2026 the company received a VA MVP task order of up to USD 18.3 million for the fourth one-year renewal option period, effective September 30, 2026.

Cash and Balance Sheet

Cash and cash equivalents were USD 98.3 million and short-term investments were USD 92.3 million, for a total of USD 190.6 million against USD 240.0 million at December 31, 2025. Net cash used in Operating Activities for nine months was USD 75.3 million against USD 52.7 million, while financing activities provided USD 33.2 million.

The company has an at-the-market Facility of USD 150.0 million, of which about USD 145.4 million remains, though it may not sell shares through it while the merger is pending. Management said current cash and investments fund near-term needs for at least 12 months and, if the merger does not close, it may seek additional equity, convertible Debt or other financing.

Data Points to Watch

Revenue of USD 25.6 million sits alongside a net loss of USD 33.8 million, nine-month net loss of USD 95.5 million and cash and investments of USD 190.6 million.

The company gave no numerical guidance. Dated items management named include the November 30, 2026 special meeting on the Tempus merger, the definitive proxy statement filed on October 21, 2026, the VA MVP task order effective September 30, 2026 and the Tempus collaboration that runs through November 25, 2029. Under the merger agreement, Tempus may elect to pay cash of USD 16.25 per share for up to 50% of shares, with the remainder in Tempus Class A stock.